Cytosorbents Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Cytosorbents Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Cytosorbents were recently set by distinguished experts, with an average mark of $3.00. If it reached this goal, it would represent a potential upside of approximately 265.85% from the previous closing price in May, 2024. The high end is $4.00, and the low is $1.00. If you're considering investing in CTSO stock, it's important to look at its competitors too.
265.85% Upside
Cytosorbents Fair Value Forecast for 2023 - 2025 - 2030
Cytosorbents's Price has increased by 100.00% In the last four years, going from $0.00 to $0.00. In the next year, analysts expect Fair Value to reach $0.88 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$755.91 | Buy/Sell | $636.99 | 16.09% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$36.91 | Buy/Sell | $44.86 | 21.92% |
| FME Stock Forecast | Fresenius Medical Care AG & Co... | Hold |
18
|
40.20€ | Buy/Sell | 41.13€ | -4.23% |
| 300529 Stock Forecast | Jafron Biomedical | Buy |
18
|
¥27.54 | Buy/Sell | ¥26.62 | 12.38% |
| EDT Stock Forecast | Spectral Medical | Buy |
0
|
C$0.45 | Buy/Sell | C$1.60 | 300.00% |
Cytosorbents Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Cytosorbents's Revenue has decreased from $41.00M to $34.69M – a 15.39% drop. In the next year, analysts expect Revenue to reach $46.95M – an increase of 35.34%. For the next seven years, the forecast is for Revenue to grow by 110.13%.
.jpg)
Cytosorbents EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Cytosorbents's EBITDA has grown from $-9.71M to $-30.64M – a 215.55% increase. In the following year, the 2 analysts surveyed believe that Cytosorbents's EBITDA will decrease by 60.93%, reaching $-11.97M. According to professionals, by 2030, Cytosorbents's EBITDA will have decreased by 58.99%, falling down to $-12.57M.
Cytosorbents EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Cytosorbents's EBIT has grown by 203.95%, rising from $-10.37M to $-31.52M. The next year, 4 experts forecast that Cytosorbents's EBIT will decrease by 46.80%, reaching $-16.77M. In 2030, professionals predict that Cytosorbents's EBIT will decrease by 108.76%, reaching $2.76M.
Cytosorbents EPS Price Prediction Forecast for 2023 - 2025 - 2030
Cytosorbents's EPS has increased by 100.00% In the last four years, going from $-0.20 to $0.00. In the next year, analysts expect EPS to reach $-0.39 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
.jpg)